At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 767 enrolled
Drug / intervention
9-valent HPV vaccine, 2 dose efficacy +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
The University of Texas Medical Branch, Galveston·interventional·Posted May 9, 2019·Updated Apr 16, 2026
In Brief
A Phase 4 clinical trial evaluating 9-valent HPV vaccine, 2 dose efficacy and 9-valent HPV vaccine, 3 doses standard timing for Immunization and 2 related conditions. Completed, enrolled 767 participants across 1 site.
Detailed Summary
The investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunization, Efficacy, Human Papilloma Virus
CountriesUnited States
CollaboratorsCancer Prevention Research Institute of Texas
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartJun 2019
Primary CompletionJan 2025
TodayJul 2026
First PostedMay 9, 2019
Enrollment StartJun 17, 2019
Primary CompletionJan 13, 2025
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 7.1 years ago
Interventions
9-valent HPV vaccine, 2 dose efficacybiological
Evaluate the efficacy of 2 doses of the HPV vaccine across a 12 month period following the 1st dose among 15-26 year old males and females.
9-valent HPV vaccine, 3 doses standard timingbiological
Will be comparison group for 2 dose efficacy group.